Opinion|Videos|June 26, 2024
Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.
Advertisement
Episodes in this series
- Dr. Efstathiou asks Dr. Freedland: What are the key factors you consider in risk stratification of your patients? What clinical characteristics and existing biomarkers help guide your assessment?
- What promising biomarkers have emerged that may help detect early signs of prostate cancer progression? (
Logan Cancers 2023 ,Kumaraswamy JCI Insight 2023 , please highlight any others)
Advertisement
Related to this article
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026
2
FDA Approves Rituximab Biosimilar for Hematologic Malignancies
3
Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC
4
Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma
5